Enanta Pharmaceuticals (ENTA) reported that the U.S. District Court of Massachusetts has rendered a decision on the summary judgment motion submitted by Pfizer, related to Enanta's patent infringement lawsuit. This lawsuit seeks damages for the alleged infringement of the '953 Patent in the production, usage, and sale of Pfizer's COVID-19 antiviral drug, Paxlovid. The court's judgment ruled in favor of Pfizer, declaring the '953 Patent invalid. Enanta intends to appeal this decision to the Court of Appeals for the Federal Circuit.
Jay Luly, CEO of Enanta Pharmaceuticals, expressed disappointment with the court's decision, stating, "We are disappointed with the Court's ruling. We believe strongly in the merits of our case, and, through the appeal process, we will continue to defend our inventions from unlawful infringement."
